Free Trial

MDxHealth Q2 2024 Earnings Report

MDxHealth logo
$1.86 -0.01 (-0.27%)
As of 02/21/2025 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDxHealth EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.26
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

MDxHealth Revenue Results

Actual Revenue
$22.16 million
Expected Revenue
$20.66 million
Beat/Miss
Beat by +$1.50 million
YoY Revenue Growth
N/A

MDxHealth Announcement Details

Quarter
Q2 2024
Time
N/A

MDXH Upcoming Earnings

MDxHealth will be holding an earnings conference call on Wednesday, February 26 at 4:30 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

MDxHealth Earnings Headlines

Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
MDxHealth sees FY25 revenue $108M-$110M, consensus $98.93M
See More MDxHealth Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MDxHealth? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MDxHealth and other key companies, straight to your email.

About MDxHealth

MDxHealth (NASDAQ:MDXH), a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

View MDxHealth Profile

More Earnings Resources from MarketBeat